European Journal of Molecular & Clinical Medicine

Abstract

Aim: To analyse clinico-mycological and therapeutic study of recurrent dermatophytic
infections and determining the right dose and duration of systemic antifungals.
Material and methods: This randomized controlled trial was conducted at the
department of DVL, Acharya Shri Chander College of Medical Sciences, Jammu from
January 2021 - May 2021 among 90 patients with superficial cutaneous fungal infection
coming to the dermatology OPD. Selected 90 patients were assigned to a trial group and
given the standard dose of the drug i.e. Tab. Itraconazole (100mg OD), Tab.
Griseofulvin (250mg BD) and Tab. Terbinafine (250mg OD). Evaluation was done by
clinical assessment in terms of clinical score. The clinical signs and symptoms assessed
were scaling, erythema, and pruritus.
Results: Tinea corporis was the principal dermatophytic lesion accounted for 93.33% of
the study subjects. Pruritus, Erythema, scaling and total scores reduced significantly in
all the drugs i.e. Griseofulvin, Itraconazole and Terbinafine. However reduction was
reported more in Itraconazole drug in our study. Complete clinical cure was reported in
3.33%, 70% and 26.67% of the subjects in Itraconazole drug at 1st visit (3w), 2nd visit
(6w) and 3rd visit (9w) respectively. No cure was reported in Griseofulvin and
Terbinafine drug at 1st visit (3w). 23.33%, 76.67% and 6.67%, 43.33% of the subjects
in Griseofulvin and Terbinafine drug were completely cured at 2nd visit (6w) and 3rd
visit (9w) respectively.
Conclusion: Itraconazole was found to be the best drug for the treatment of
dermatophytes among the tested antifungals.